A phase III, randomised, open-label, comparative safety and efficacy trial of in-travenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia who are intolerant or unresponsive to oral iron therapy or in whom the haemoglobin measurement in Investigators' opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion

Back
To top